Pharm-Olam, InSite Vision Complete Phase 3 Clinical Study

Pharm-Olam International, contract research organization for InSite Vision, has completed a Phase 3 clinical trial of BromSite, an anti-inflammatory designed to reduce swelling and pain after cataract surgery.

The study included 268 cataract surgery patients. BromSite was administered the day of surgery and twice a day for two weeks post-surgery. The trial, designed to determine the safety and efficacy of the treatment, showed promising results.

More Articles on Ophthalmology:
American Academy of Ophthalmology Cautionary Campaign Gains Public Awareness
Las Vegas New Eyes, Eye Care Associates Partner
OptiMedica Laser System Clinical Presentations to be Shown at ASCRS 2013


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast